{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Denmark Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/dk/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/dk/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Denmark, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:0bca75b8bbc2a8fa3539987191796c6707dd6e26260af2ed0b559caa56026031", "url": "https://finance.yahoo.com/healthcare/articles/invitation-presentation-alk-first-six-140600422.html", "external_url": "https://finance.yahoo.com/healthcare/articles/invitation-presentation-alk-first-six-140600422.html", "title": "Invitation to the presentation of ALK\u2019s first six months (Q2) 2026 results on Thursday, 20 August 2026", "content_text": "ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK's management will comment on the results for the first six months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen S\u00f8lje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be available for replay on ALK's", "date_published": "2026-08-13T14:06:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALK-B", "name": "ALK-Abell\u00f3 A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e5a5798a-6e6b-48ed-9dec-153219564368/"}]}}, {"id": "source:6a9ef7de3c3c4e0f617168c7947a2a19328d0a9ca572f6c5356f91e1ea48ad7b", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-zldpf-surpasses-q2-113502082.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-zldpf-surpasses-q2-113502082.html", "title": "Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates", "content_text": "Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2,150.00%. A quarter ago, it was expected that this company would post a loss of $1.57 per share when it actually produced a loss of $0.87, delivering a surprise of +44.59%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Zealand Pharma AS, w", "date_published": "2026-08-13T11:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:1eb3095fe93db01645050a1f2e1ca1911617c4100f31d438c0109b8dc54343fc", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-cpse-zeal-stock-081006793.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-cpse-zeal-stock-081006793.html", "title": "Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain. Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story. The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on s", "date_published": "2026-08-13T08:10:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:4c47be21db0b869f236a4343c9b21e0fe0351201a70508d8b2df37feae0ef95f", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-announces-financial-results-050000185.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-announces-financial-results-050000185.html", "title": "Zealand Pharma Announces Financial Results for the First Half of 2026", "content_text": "Zealand Pharma Company announcement \u2013 No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy. Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living wit", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:00065397cad77d25ae4cd46e71184695e7fc762987d47000af0a47dbe12b1e59", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-cpse-zeal-royalty-231634640.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-cpse-zeal-royalty-231634640.html", "title": "Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase and sale deal with Royalty Pharma linked to rusfertide, a potential treatment for polycythemia vera. The agreement transfers Zealand Pharma's economic interests related to rusfertide, including potential future royalty rights. It also provides new funding that management plans to redeploy toward the company's key prior", "date_published": "2026-08-12T23:16:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:a6325fa22040e5dc4401ff094910036d501da606af5903010ffd9c8a18c147eb", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-zealand-pharma-enter-201000247.html", "external_url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-zealand-pharma-enter-201000247.html", "title": "Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million", "content_text": "Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder. \"We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health,\" said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. \"This transaction underscores Royalty Pharma's role as a long-term, trusted partner to biopharma companies as they advance important medicines. Furthermore, we believe rusfertide has the potential to become a transformative treatment option for patients with polycythemia vera, and we look forward to its continued progress through regulatory review.\" \"We are very pleased to work with Royalty Pharma, a leading funder of life science innovation, on this strategic financial transaction,\" said Henriette Wennicke, Chief Financial Officer at Zealand Pharma. \"This agreement converts a future potential royalty stream into immediate capital that will be redeployed against future growth opportunities in line with our key strategic priorities under our Metabolic Frontier 2030 strategy.\" Rusfertide is a potential first-in-class therapy that mimics the action of hepcidin, a natural hormone that regulates iron homeostasis and red blood cell production. By targeting the underlying mechanism of iron dysregulation in polycythemia vera, rusfertide aims to reduce excess red blood cell production and help patients achieve sustained hematocrit control. Rusfertide is administered once weekly via subcutaneous self-injection and has been generally well-tolerated in clinical trials to date. The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for rusfertide for the treatment of adults with polycythemia vera in the third quarter of 2026i and Takeda will be responsible for global commercialization. Transaction terms Under the terms of the royalty purchase and sale agreement, Royalty Pharma will provide $100 million to Zealand Pharma in exchange for its economic interests related to rusfertide, including rights to a 1% royalty on potential future global net sales of rusfertide and regulatory and commercial milestones. This consists of $50 million upon closing of the transaction with the remaining $50 million due upon the first anniversary of the closing of the agreement. Zealand Pharma will retain the right to a 0.25% royalty on annual net global sales of rusfertide greater than $1.5 billion, while Royalty Pharma will retain a 0.75% royalty on sales above $1.5 billion. Story Continues Background In June 2012, Zealand Pharma and Protagonist Therapeutics, Inc., entered into a research collaboration agreement to develop disulfide-rich peptides (DRPs). Under the agreement, Zealand Pharma was responsible for preclinical and clinical drug development of DRPs discovered under the collaboration. The research collaboration was terminated in 2014 and Protagonist's payment obligations to Zealand Pharma were clarified in a settlement agreement reached in 2021. In January 2024, Protagonist and Takeda entered into a worldwide license and collaboration agreement for rusfertide. Advisors Covington, Dechert, Jones Day and Kromann acted as legal advisors to Royalty Pharma. Goodwin acted as legal advisor to Zealand Pharma. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical compani", "date_published": "2026-08-12T20:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:ad815a30e5c1a40c334a1b739029cbfe341e613cdf0512338a7f3ca45284208d", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-enters-usd-100-200500756.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-enters-usd-100-200500756.html", "title": "Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide", "content_text": "Zealand Pharma Company announcement \u2013 No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide. The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharma's key strategic priorities. Copenhagen, Denmark, August 12, 2026 \u2013 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ", "date_published": "2026-08-12T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:e6b8fb8b7756e99aa4374c23943f6e0a9e8a1e41130e8092aada209c9a6372c1", "url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "content_text": "Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 \u2013 Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,702 shares at DKK 1,334.50, 2,069 shares at DKK 1,362.50, and 17,821 shares at DKK 1,615.00. Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04% of the Company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly. Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,377,844 which is made up of 62,377,844 shares of a nominal value of DKK 1 each, corresponding to 62,377,844 votes. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X. Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Company Announcement contains forward looking statements. The words \"believe,\" \"expect,\" \"anticipate,\" \"intend\" and \"plan\" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward ", "date_published": "2026-08-11T17:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "GMAB"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMAB", "name": "Genmab A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1a591078-2b4b-4c42-9ccb-8d5fba81165f/"}]}}, {"id": "source:b9c761b005c2ccc85568e4eabdb7719772386434822950f8b29a3ed646a289fd", "url": "https://finance.yahoo.com/markets/stocks/articles/bioharvest-sciences-inc-bhst-reports-111001198.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bioharvest-sciences-inc-bhst-reports-111001198.html", "title": "BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates", "content_text": "BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -30.77%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.11, delivering a surprise of +15.38%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. BioHarvest Sciences Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.84 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 10.51%. This compares to year-ago revenues of $8.52 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BioHarvest Sciences Inc. shares have lost about 59.5% since the beginning of the year versus the S&P 500's gain of 13.3%. What's Next for BioHarvest Sciences Inc.? While BioHarvest Sciences Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BioHarvest Sciences Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story Continues It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $11.51 million in revenues for the coming quarter and -$0.45 on $43.01 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Zealand Pharma A/S (ZLDPF), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13. This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -102.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Zealand Pharma A/S's revenues are expected to be $81.55 million, down 94.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioHarvest Sciences Inc. (BHST) : Free Stock Analysis Report Zealand Pharma A/S (ZLDPF) : Free Stock Ana", "date_published": "2026-08-11T11:10:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:1ab483cdb822eca8bd11e3ca4e52d97708df8e1d0115e1c7cbabc6db033a6a77", "url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-holdings-inc-obio-215506647.html", "external_url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-holdings-inc-obio-215506647.html", "title": "Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates", "content_text": "Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.57%. A quarter ago, it was expected that this company would post a loss of $0.4 per share when it actually produced a loss of $0.33, delivering a surprise of +17.5%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Orchestra BioMed Holdings, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.09 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 32.31%. This compares to year-ago revenues of $0.84 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Orchestra BioMed Holdings, Inc. shares have added about 2.2% since the beginning of the year versus the S&P 500's gain of 13.3%. What's Next for Orchestra BioMed Holdings, Inc.? While Orchestra BioMed Holdings, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Orchestra BioMed Holdings, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story Continues It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.37 on $0.12 million in revenues for the coming quarter and -$1.47 on $0.48 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Zealand Pharma A/S (ZLDPF), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13. This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -102.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Zealand Pharma A/S's revenues are expected to be $81.55 million, down 94.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Orchestra BioMed Holdings, Inc. (OBIO) : Free Stock Analysis Report ", "date_published": "2026-08-10T21:55:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:4a81e75201b2b09ef5feb33aaac4d2a700ce6f406ee5f208e767a4f5bc08b72c", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-transactions-related-share-150000162.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-transactions-related-share-150000162.html", "title": "Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)", "content_text": "Zealand Pharma Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 \u2013 Zealand Pharma A/S (\"the Company\" or \"Zealand Pharma\") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the \"Program\") for week 32 (August 3 - August 7, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, \"MAR\") and Commission Delegated R", "date_published": "2026-08-10T15:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}]}